by The global central nervous system therapeutics market size is projected to grow from USD 120.64 billion in 2021 to USD 209.2 billion by 2030, at a CAGR of 6.3% from 2021 to 2030, According to Canada based company by Precedence Research. The report contains 150+ pages with detailed analysis.
The base year for the study has been considered 2021, the historic year 2017 and 2020, the forecast period considered is from 2021 to 2030. The central nervous system therapeutics market is analyzed on the basis of value (US$ Million), volume (Unit), and price (US$/Unit).
The rising prevalence of various central nervous system diseases among the population such as Alzheimer’s disease, Parkinson’s disease, brain cancer, anxiety disorders, and epilepsy is a major factor that drives the demand for the central nervous system therapeutics. As per the Alzheimer’s Association, over 5million people are affected with the Alzheimer’s diseases and this number is projected to reach 14 million by 2050. It is estimated that around 300,000 people were diagnosed with brain cancer across the globe in 2018 around 240,000 people died in the same year due to it.
Download the FREE Sample Report (Including TOC, List of Tables & Figures, and Chart) @ https://www.precedenceresearch.com/sample/1523
Moreover, the rising awareness regarding the various central nervous system diseases is fueling the demand for the CNS therapeutics across the globe. The rising investments by the top market players to develop novel therapies and diagnostic tests is expected to significantly influence the market growth. Furthermore, the presence of strong pipeline therapeutics is fostering the sales of the CNS therapeutics, thereby driving the growth of the global central nervous system therapeutic market.
Report Highlights
- Based on the disease, the neurodegenerative diseases segment dominated the global central nervous system therapeutic market, garnering a market of around 40% in 2020. This is attributed to the increasing prevalence of diseases like Parkinson’s disease, Alzheimer’s disease, and multiple sclerosis. According to the Alzheimer’s Association, around 14 million people will be suffering from Alzheimer’s disease by 2050 across the globe. The growing geriatric population is increasing the risks of Parkinson’s disease and hence this segment is expected to sustain its significance throughout the forecast period.
Scope of the Central Nervous System Therapeutic Market
| Report Coverage | Details |
| Market Size | US$ 209.2 Billion by 2030 |
| Growth Rate | CAGR of 6.3% from 2021 to 2030 |
| Largest Market | North America |
| Fastest Growing Market | Asia Pacific |
| Base Year | 2021 |
| Forecast Period | 2021 to 2030 |
| Segments Covered | Disease Type, Region |
Market Dynamics
Driver
Rising prevalence of neurological disorders owing to the growing geriatric population
According to the Parkinson’s Foundation, the risks of getting Parkinson’s disease increases with age. Therefore the growing geriatric population across the globe is expected to fuel the growth of the global central nervous system therapeutic market. According to the United Nations, the global geriatric population is expected to reach at 2 billion by 2050 and around 80% of this population will be living in the low and middle income countries. Therefore, the developing countries presents a lucrative growth opportunity for the market players during the forecast period.
Restraint
Stringent regulations and time-consuming approval process
The research & developmental activities associated in the development of novel therapies for the central nervous system diseases is a costly and time consuming process. Therefore, the research results and clinical trials involves a lot of time. Moreover, the stringent government regulations regarding the therapies presents a challenge to the manufacturers. The high time-consuming process and huge costs involved may hamper the growth of the global central nervous system therapeutic market.
Opportunity
New product launches and approvals
The market players are investing heavily in the new product developments and seeking approvals from the concerned authorities. These new launches and may provide growth aspects to the players in the forthcoming future. For instance, in February 2020, Biogen and Sangamo Therapeutics entered into a deal of US$2.7 billion for developing a gene regulation therapy for the treatment of Alzheimer’s disease.
Challenge
Lack of adequate healthcare infrastructure
The developing and the underdeveloped countries suffers from the lack of adequate access to the basic healthcare facilities. This results in under treatment. Most of the patients remain undiagnosed and untreated. This is a major challenge for the market.
Regional Snapshot
North America accounted for more than 45% of the revenue share and dominated the global central nervous system therapeutic market in 2020. This is attributed to the growing geriatric population and rising prevalence of various CNS diseases. As per the Parkinson’s Foundation, about 60,000 people are diagnosed with Parkinson’s disease in US each year and around 1 million people are living with Parkinson’s disease in US.It is estimated that approximately 70,800 people are affected with brain cancer every year in the US, which causes 2.4% of the total cancer deaths in US. As per the GBD 2019, neurological diseases are the fourth major causes of death in US and third in Canada. The increased awareness regarding various central nervous system diseases among the population has fostered the demand for the CNS therapeutics in North America.
Asia Pacific is estimated to be the most opportunistic market during the forecast period. Asia Pacific is witness a surge in the number of patients affected with the central nervous system diseases such as dementia, anxiety disorders, Alzheimer’s disease, and Parkinson’s disease. The non-profit organizations are providing cost-free treatment for the CNS diseases and playing a crucial role in spreading the awareness about mental health. The emerging nations like China and India are foreseeing increased investments in the development of healthcare infrastructure. The improving access to advanced healthcare facilities and diagnostic tests are expected to fuel the growth of the Asia Pacific central nervous system therapeutic market.
Key Companies & Market Share Insights
The market is moderately fragmented with the presence of several local companies. These market players are striving to gain higher market share by adopting strategies, such as investments, partnerships, and acquisitions & mergers, novel product introductions and developments, promotion strategies and Research and Development (R&D) activities in the marketplace. Companies are also spending on the development of improved products. Moreover, they are also focusing on maintaining competitive pricing. The competitive profiling of these players includes business and financial overview, gross margin, production, sales, and recent developments which can aid in assessing competition in the market.
Some of the major players in the global central nervous system therapeutics market include:
- Biogen Inc.
- Otsuka Pharmaceutical Co. Ltd
- Eli Lilly and Company
- Merck & Co.
- AstraZeneca
- Takeda Pharmaceutical Company Limited
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Johnson & Johnson Private Limited
- Pfizer Inc.
- GlaxoSmithKline PLC
Segments Covered in the Report
By Disease
- Neurovascular Diseases
- Mental Health
- Anxiety Disorders
- Mood Disorders
- Epilepsy
- Psychotic Disorders
- Others
- Neurodegenerative Diseases
- Parkinson’s Disease
- Alzheimer’s Disease
- Amyotrophic Lateral Sclerosis
- Multiple Sclerosis
- Huntington’s Disease
- Others
- CNS Trauma
- CNS Cancer
- Infectious Diseases
- Others
By Geography
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Malaysia
- Philippines
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC
- North Africa
- South Africa
- Rest of the Middle East & Africa
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Central Nervous System Therapeutic Market
5.1. COVID-19 Landscape: Central Nervous System Therapeutic Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Central Nervous System Therapeutic Market, By Disease
8.1. Central Nervous System Therapeutic Market, by Disease Type, 2020-2027
8.1.1. Neurovascular Diseases
8.1.1.1. Market Revenue and Forecast (2016-2027)
8.1.2. Mental Health
8.1.2.1. Market Revenue and Forecast (2016-2027)
8.1.3. Neurodegenerative Diseases
8.1.3.1. Market Revenue and Forecast (2016-2027)
8.1.4. CNS Trauma
8.1.4.1. Market Revenue and Forecast (2016-2027)
8.1.5. CNS Cancer
8.1.5.1. Market Revenue and Forecast (2016-2027)
8.1.6. Infectious Diseases
8.1.6.1. Market Revenue and Forecast (2016-2027)
8.1.7. Others
8.1.7.1. Market Revenue and Forecast (2016-2027)
Chapter 9. Global Central Nervous System Therapeutic Market, Regional Estimates and Trend Forecast
9.1. North America
9.1.1. Market Revenue and Forecast, by Disease (2016-2027)
9.1.2. U.S.
9.1.3. Rest of North America
9.1.3.1. Market Revenue and Forecast, by Disease (2016-2027)
9.2. Europe
9.2.1. Market Revenue and Forecast, by Disease (2016-2027)
9.2.2. UK
9.2.2.1. Market Revenue and Forecast, by Disease (2016-2027)
9.2.3. France
9.2.3.1. Market Revenue and Forecast, by Disease (2016-2027)
9.2.4. Rest of Europe
9.2.4.1. Market Revenue and Forecast, by Disease (2016-2027)
9.3. APAC
9.3.1. Market Revenue and Forecast, by Disease (2016-2027)
9.3.2. India
9.3.2.1. Market Revenue and Forecast, by Disease (2016-2027)
9.3.3. China
9.3.3.1. Market Revenue and Forecast, by Disease (2016-2027)
9.3.4. Japan
9.3.4.1. Market Revenue and Forecast, by Disease (2016-2027)
9.3.5. Rest of APAC
9.3.5.1. Market Revenue and Forecast, by Disease (2016-2027)
9.4. MEA
9.4.1. Market Revenue and Forecast, by Disease (2016-2027)
9.4.2. GCC
9.4.2.1. Market Revenue and Forecast, by Disease (2016-2027)
9.4.3. North Africa
9.4.3.1. Market Revenue and Forecast, by Disease (2016-2027)
9.4.4. South Africa
9.4.4.1. Market Revenue and Forecast, by Disease (2016-2027)
9.4.5. Rest of MEA
9.4.5.1. Market Revenue and Forecast, by Disease (2016-2027)
9.5. Latin America
9.5.1. Market Revenue and Forecast, by Disease (2016-2027)
9.5.2. Brazil
9.5.2.1. Market Revenue and Forecast, by Disease (2016-2027)
9.5.3. Rest of LATAM
9.5.3.1. Market Revenue and Forecast, by Disease (2016-2027)
Chapter 10. Company Profiles
10.1. Biogen Inc.
10.1.1. Company Overview
10.1.2. Product Offerings
10.1.3. Financial Performance
10.1.4. Recent Initiatives
10.2. Otsuka Pharmaceutical Co. Ltd
10.2.1. Company Overview
10.2.2. Product Offerings
10.2.3. Financial Performance
10.2.4. Recent Initiatives
10.3. Eli Lilly and Company
10.3.1. Company Overview
10.3.2. Product Offerings
10.3.3. Financial Performance
10.3.4. Recent Initiatives
10.4. Merck & Co.
10.4.1. Company Overview
10.4.2. Product Offerings
10.4.3. Financial Performance
10.4.4. Recent Initiatives
10.5. AstraZeneca
10.5.1. Company Overview
10.5.2. Product Offerings
10.5.3. Financial Performance
10.5.4. Recent Initiatives
10.6. Takeda Pharmaceutical Company Limited
10.6.1. Company Overview
10.6.2. Product Offerings
10.6.3. Financial Performance
10.6.4. Recent Initiatives
10.7. Novartis AG
10.7.1. Company Overview
10.7.2. Product Offerings
10.7.3. Financial Performance
10.7.4. Recent Initiatives
10.8. Teva Pharmaceutical Industries Ltd.
10.8.1. Company Overview
10.8.2. Product Offerings
10.8.3. Financial Performance
10.8.4. Recent Initiatives
Chapter 11. Research Methodology
11.1. Primary Research
11.2. Secondary Research
11.3. Assumptions
Chapter 12. Appendix
12.1. About Us
12.2. Glossary of Terms
Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.
Why Buy this Report?
The purpose of Precedence Research’s central nervous system therapeutics market study is to provide stakeholders with a detailed picture of potential barriers and untapped opportunities. The report contains exclusive information to assist businesses in making informed decisions about how to maintain growth throughout the assessment period.
Buy Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1523
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
